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Abstract
Background: To investigate the association between CHADS2 score, depressive symptoms, and quality of life in a
large general population from China.
Methods: A cross-sectional study of 11,956 permanent residents of Liaoning Province in China ≥ 35 years of age
was conducted between January and August 2013 (response rate 85.3%). All participants completed a
questionnaire, had a physical examination, and underwent blood examination. Depressive symptoms were assessed
with the Patient Health Questionnaire-9 (PHQ-9), while the quality of life (QoL) was measured using the World
Health Organization Quality of Life Brief Scale (WHOQOL-BREF).
Results: With increasing CHADS2 score, the prevalence of depressive symptoms increased from 4.9 to 27.8% (P < 0.001),
and all scores of WHOQOL-BREF decreased significantly (all Ps < 0.001). After adjusting for confounding risk factors,
subjects with CHADS2 score≥ 3 had higher risk of depressive symptoms than those with CHADS2 score = 0 (all Ps < 0.05).
Also, CHADS2 score was negatively associated with all scores of WHOQOL-BREF (all Ps < 0.001). Furthermore, subjects with
any item in CHADS2 had higher prevalence of depressive symptoms (all Ps < 0.001). Heart failure and stroke remained
independently associated with depressive symptoms after adjusting for confounding risk factors
and other items (Ps < 0.001), while heart failure, age≥ 75 years, diabetes mellitus, and stroke were all independently
negatively associated with the total score of WHOQOL-BREF (all Ps < 0.05).
Conclusions: The CHADS2 score is significantly associated with depressive symptoms and impaired quality of life in the
general population.
Keywords: CHADS2 score, Patient Health Questionnaire-9, World Health Organization Quality of Life Brief Scale,
Depressive symptoms, Quality of life
Background
Depression is a worldwide public health problem [1, 2],
and depressive disorder has become one of the leading
causes of worldwide disability [3], which could contribute
to an increased risk of all-cause mortality [4]. High preva-
lence of depression has been reported in patients with
cardiovascular diseases (CVD) and its presence increases
the risk for adverse cardiovascular events [5]. However,
the awareness of depressive symptoms among such popu-
lation is quite low and the majority of them are not appro-
priately treated and controlled. Therefore, identifying all
the epidemiological characteristics for depressive symp-
toms will help to create population-based strategies to
prevent and treat this serious health problem.
In recent years, the measurement of health has been
broadened beyond traditional health indicators such as
mortality and morbidity. Thus, quality of life (QoL) is
defined by the World Health Organization (WHO) as
individuals’ perceptions of their position in life in the
context of the culture and value systems in which they
live and in relation to their goals, expectations, standards
and concerns [6]. It has received growing attention re-
cently, and can be impaired in patients with established
CVD [7] or in individuals at high risk of CVD [8].* Correspondence: yxsun@cmu.edu.cn
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The CHADS2 score is a simple but reliable clinical
scheme, which includes congestive heart failure, hyperten-
sion, age ≥ 75 years, diabetes mellitus, and prior stroke or
transient ischemic attack. It has been widely used to assess
the risk of stroke for patients with atrial fibrillation (AF)
[9, 10]. Moreover, the application of the CHADS2 score
was not limited in AF population or assessing the risk of
stroke in recent studies. In patients with acute coronary
syndrome with or without AF, the score could be used as
a risk assessment tool for mortality [11]. Furthermore, the
score is newly found to be associated with peripheral
arterial occlusive disease in patients without AF [12].
However, the association of the CHADS2 score with de-
pressive symptoms and QoL has never been reported, even
though the prevalence of depression has been proved to be
apparently higher in heart failure [13], hypertension [14],
diabetes [15], and stroke [16] than in the general population
[17]. Therefore, the current study was designed to explore
the association between the CHADS2 score, depressive
symptoms, and QoL in a general Chinese population.
Methods
Study population
A representative sample of men and women ≥ 35 years of
age from Liaoning Province was recruited between January
2013 and August 2013, using a multi-stage, randomly strati-
fied, cluster-sampling scheme, which is called the Northeast
China Rural Cardiovascular Health Study (NCRCHS). And
our current study about CHADS2 score, depressive symp-
toms, and quality of life was part of the NCRCHS. Three
counties (Dawa, Zhangwu, and Liaoyang) were selected
from the eastern, southern, and northern regions of
Liaoning Province. One township near a city in each county
was randomly selected giving a total of three townships. Six
to eight villages from each township were randomly
selected to give a total of 26 rural villages. All of the eligible
permanent residents aged ≥ 35 years from each village
(n = 14,016) were invited to participate in the study,
and 11,956 (response rate 85.3%) agreed to do so.
Participants with pregnancy and malignant tumor were
excluded from the present study. And subjects with se-
vere mental disorders (for example psychosis) who
couldn’t complete the face-to-face survey of NCRCHS
were also excluded.
The study was approved by the Ethics Committee of
China Medical University (Shenyang, China). All proce-
dures were performed in accordance with the ethical
standards. Written consent was obtained from all partic-
ipants after they had been informed of the study’s
objectives, benefits, medical procedures, and confidenti-
ality safeguards for personal information. In the case of
an illiterate participant, written informed consent was
obtained from the appropriate legal proxy.
Data collection and measurement
Data were collected during a single clinic visit by doc-
tors and trained nurses using a standard questionnaire
in a face-to-face interview. All potential investigators
had received training on the objectives of the study, how
to administer the questionnaire, the standard methods
of measurement, the importance of standardization, and
study procedures. Only those who earned a perfect score
on a post-training test were allowed to participate as
study investigators. During data collection, the inspec-
tors received further instructions and support.
Data on the demographic characteristics, lifestyle risk
factors, family income, medical history of hypertension,
congestive heart failure, stroke, diabetes mellitus, depressive
symptoms, and quality of life were obtained, as described
above, by interview with the standardized questionnaire.
There was a central steering committee with a subcommit-
tee for quality control that made sure all data were
collected according to well-known standards.
Depressive symptoms
Depressive symptoms were assessed using the Patient
Health Questionnaire-9 (PHQ-9), which was a 9-item
screening instrument and widely used in primary health
centers with high reliability and validity [18, 19]. Partici-
pants were asked how often, over the past 2 weeks, they
had been bothered by each of the depressive symptoms
with the score ranging from 0 to 3. Then, the total score of
PHQ-9 ranged from 0 to 27. The severity of depressive dis-
order was considered mild for score of 5 to 9, moderate for
score of 10 to 14, moderately severe for score of 15 to 19
and severe for score of 20 to 27. A PHQ-9 score ≥ 10 was
recommended as the cut-off score for detecting major
depressive disorders [20].
Quality of life
The quality of life was measured with the World Health
Organization Quality of Life Brief Scale (WHOQOL-BREF),
which was a self-report inventory with 26 original items [21,
22]. The items fell into four domains: the physical health (7
items), the psychological health (6 items), the social relation-
ships (3 items), and the environment (8 items), together with
2 items measuring the overall QoL and general health. Each
item was answered on a 5-point response scale, and the
range of score for each domain was from 4 to 20 after calcu-
lation, with higher score indicating better QoL.
CHADS2 score
The CHADS2 score was calculated for each subject
based on the point system with 2 points for a history of
stroke and 1 point for congestive heart failure, hyperten-
sion, an age ≥ 75 years and diabetes mellitus. Congestive
heart failure was assigned positive if they had ever been
told by a physician that they had congestive heart failure
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[23]. Similarly, stroke was defined as a history of prior
stroke or transient ischemic attack. Hypertension was
defined as a systolic blood pressure (SBP) ≥ 140 mmHg
and/or diastolic blood pressure (DBP) ≥ 90 mmHg and/
or the use of antihypertensive medications according to
the Eighth Joint National Committee on the guidelines
for the management of high blood pressure in adults
(JNC-8) [24]. World Health Organization criteria were
followed for defining diabetes mellitus (fasting blood
glucose ≥ 7.0 mmol/L or 126 mg/dL, and/or being on
treatment for diabetes) [25].
Covariate measurements
Weight and height were measured to the nearest 0.1 kg
and 0.1 cm, respectively, with the participants in lightweight
clothing without shoes. The body mass index (BMI) was
calculated as weight in kilograms divided by the square of
the height in meters.
Fasting blood samples were collected in the morning
after ≥ 8 h of fasting for all participants. Blood samples were
obtained from an antecubital vein using BD Vacutainer
tubes containing EDTA. Serum was subsequently isolated
from whole blood, and all serum samples were frozen at
−20 °C for testing at a central, certified laboratory. Fasting
blood glucose (FBG), total cholesterol (TC), triglycerides
(TG), high density lipid cholesterol (HDL-C), low density
lipid cholesterol (LDL-C), serum uric acid, serum creatin-
ine, and other routine blood indices were analyzed enzy-
matically on an auto-Analyzer. Glomerular filtration rate
(GFR) was estimated using the equation originating from
the Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) equation [26].
Physical activity included occupational and leisure-time
physical activity, and a detailed description of these stan-
dards has been presented [27]. The combination of occupa-
tional and leisure-time physical activity was therefore
described as low (light levels of activity in both categories),
moderate (moderate or high levels of activity in one of the
categories), or high (moderate or high levels of activity in
both categories).
Statistical analysis
All statistical analyses were performed using SPSS 17.0 soft-
ware (SPSS Inc., Chicago, IL, USA). Differences between
groups were compared using two-tailed Student’s t-test,
ANOVA or the χ2 test as appropriate. The prevalences of de-
pressive symptoms among different CHADS2 score were cal-
culated, and the total score of WHOQOL-BREF by PHQ-9
score and CHADS2 score was also presented. Both univariate
and multivariate logistic regression analyses were performed
to estimate the crude and independent associations between
each item in CHADS2, CHADS2 score, and depressive symp-
toms. Multivariate linear regression analysis and optimal scale
regression analysis were conducted to assess the independent
associations of each item in CHADS2 and CHADS2 score
with WHOQOL-BREF score, respectively. P < 0.05 was con-
sidered as statistically significant.
Results
Characteristics of the study population
Of the 11,956 participants, 896 had incomplete data and
were excluded from the analysis, leaving a total of 11,060
participants (5080 men and 5980 women) with a mean age
of 53.9 years. The subjects with moderate or severe depres-
sive symptoms were significantly older and had lower per-
centage of men than those with no or mild depressive
symptoms (Ps < 0.001) (Table 1). The subjects with moder-
ate or severe depressive symptoms had significantly higher
FBG, TG (all Ps < 0.05), and lower eGFR levels (P < 0.001).
They also had a lower percentage of alcohol drinking and
smoking and lower levels of education, income, physical ac-
tivity and sleep time (all Ps < 0.001). In addition, the subjects
with moderate or severe depressive symptoms had signifi-
cantly higher levels of CHADS2 score and lower scores of
WHOQOL-BREF (all Ps < 0.001). However, there were no
significant differences in BMI, SBP, DBP, TC, HDL-C, LDL-
C, or serum uric acid between the two groups.
Prevalence of depressive symptoms and QoL by CHADS2
score
The prevalence of depressive symptoms (PHQ-9 score ≥
10) by CHADS2 score was summarized (Fig. 1 and Table 2).
It was found that the percentage of subjects with depres-
sive symptoms increased significantly with increasing
CHADS2 score, from the lowest of 4.9% to the highest of
27.8% (P < 0.001). The QoL evaluated by WHOQOL-BREF
was described according to CHADS2 score (Table 3). As a
result, the mean scores for total and every domain of
WHOQOL-BREF decreased significantly with increasing
CHADS2 score (all Ps < 0.001). The association of CHADS2
score with the total score of WHOQOL-BREF stratified by
depressive symptoms was also examined and presented
(Fig. 2). The total score of WHOQOL-BREF decreased
siginificantly with increasing CHADS2 score in both sub-
groups (Ps < 0.001). The lowest level of total score was
found in subjects with CHADS2 score of 0, while the high-
est was in those with CHADS2 score of 5.
Association between CHADS2 score and depressive symptoms
The associations between each item in CHADS2, CHADS2
score and depressive symptoms were examined by univar-
iate and multivariate logistic regression analyses (Table 2).
Heart failure and stroke were independently associated
with depressive symptoms after adjusting for other items
in CHADS2 and clinical covariates, including gender, BMI,
TC, TG, LDL-C, HDL-C, serum uric acid, eGFR, smoking,
drinking, education, income, physical activity, and sleep
time (Ps < 0.001). However, the associations between
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Table 1 Comparison of the characteristics of the study sample
Variable All
(n = 11,060)





Age, years 53.9 ± 10.5 53.7 ± 10.5 57.1 ± 10.2 <0.001
Male 5080 (45.9) 4898 (47.1) 182 (27.2) <0.001
BMI, kg/m2 24.8 ± 3.7 24.8 ± 3.7 24.5 ± 3.8 0.050
SBP, mmHg 141.6 ± 23.3 141.5 ± 23.2 143.5 ± 25.5 0.051
DBP, mmHg 82.0 ± 11.7 82.0 ± 11.7 82.2 ± 11.8 0.603
FBG, mmol/L 5.91 ± 1.62 5.90 ± 1.61 6.09 ± 1.76 0.006
TC, mmol/L 5.24 ± 1.09 5.23 ± 1.08 5.31 ± 1.18 0.124
TG, mmol/L 1.63 ± 1.47 1.62 ± 1.47 1.75 ± 1.51 0.030
HDL-C, mmol/L 1.41 ± 0.38 1.41 ± 0.38 1.40 ± 0.40 0.601
LDL-C, mmol/L 2.93 ± 0.82 2.92 ± 0.82 2.96 ± 0.89 0.290
Serum uric acid, umol/L 292 ± 85 292 ± 85 289 ± 90 0.344
eGFR, ml/min/1.73 m2 92.8 ± 15.9 93.1 ± 15.7 88.6 ± 18.3 <0.001
Current smoker 3886 (35.1) 3693 (35.5) 193 (28.8) <0.001
Current drinker 2474 (22.4) 2402 (23.1) 72 (10.7) <0.001
Education level <0.001
≤ Primary school 5539 (50.1) 5095 (49.0) 444 (66.3)
Middle school 4491 (40.6) 4296 (41.3) 195 (29.1)
≥ High school 1030 (9.3) 999 (9.6) 31 (4.6)
Family income, CNY/year <0.001
≤ 5000 1379 (12.5) 1209 (11.6) 170 (25.4)
5000–20,000 6025 (54.5) 5655 (54.4) 370 (55.2)
> 20,000 3656 (33.1) 3526 (33.9) 130 (19.4)
Physical activity <0.001
Low 3263 (29.5) 2953 (28.4) 310 (46.3)
Moderate 7164 (64.8) 6830 (65.7) 334 (49.9)
High 633 (5.7) 607 (5.8) 26 (3.9)
Sleep duration, h/day 7.3 ± 1.7 7.3 ± 1.6 6.2 ± 2.1 <0.001
Congestive heart failure 102 (0.9) 78 (0.8) 24 (3.6) <0.001
Hypertension 5623 (50.8) 5234 (50.4) 389 (58.1) <0.001
Age≥ 75 years 332 (3.0) 297 (2.9) 35 (5.2) 0.001
Diabetes mellitus 1154 (10.4) 1051 (10.1) 103 (15.4) <0.001
Stroke 976 (8.8) 848 (8.2) 128 (19.1) <0.001
CHADS2 score 0.83 ± 0.96 0.80 ± 0.94 1.20 ± 1.25 <0.001
WHOQOL-BREF domain
Physical health 15.1 ± 2.3 15.4 ± 2.1 11.5 ± 2.5 <0.001
Psychological 14.5 ± 2.4 14.8 ± 2.2 10.7 ± 2.6 <0.001
Social relationships 14.6 ± 2.1 14.7 ± 2.0 13.0 ± 2.4 <0.001
Environment 13.5 ± 2.1 13.6 ± 2.1 11.7 ± 2.1 <0.001
Data are expressed as mean ± standard deviation or n (%)
Abbreviations: BMI body mass index, CNY China Yuan, DBP diastolic blood pressure, FBG fasting blood glucose, eGFR estimated glomerular filtration rate, HDL-C
high density lipid cholesterol, LDL-C low density lipid cholesterol, SBP systolic blood pressure, TC total cholesterol, TG triglycerides, WHOQOL-BREF the World
Health Organization Quality of Life Brief Scale
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hypertension, age ≥ 75 years, diabetes mellitus and depres-
sive symptoms were significant only in univariate model
(Ps ≤ 0.001) but not in multivariate model (Ps > 0.05). Sub-
jects with CHADS2 score ≥ 3 had significantly higher inde-
pendent risk of depressive symptoms than those with
CHADS2 score = 0 after adjusting for clinical covariates
(all Ps < 0.05).
Association between CHADS2 score and QoL
To explore the associations between CHADS2 score and
QoL, a multivariate linear regression analysis was con-
ducted for each item in CHADS2, and optimal scale re-
gression analysis was used for CHADS2 score (as ordinal
variate) (Table 4). Generally speaking, items in CHADS2
were negatively associated with scores of WHOQOL-
BREF. Congestive heart failure, age ≥ 75 years, diabetes
mellitus, and stroke were all independently negatively as-
sociated with the total score of WHOQOL-BREF after
adjusting for gender, BMI, TC, TG, LDL-C, HDL-C, serum
uric acid, eGFR, smoking, drinking, education, income,
physical activity, sleep time, and other items in CHADS2
(all Ps < 0.05). Optimal scale regression analysis showed
CHADS2 score was independently negatively associated
with all scores of WHOQOL-BREF (all Ps < 0.001).
Discussion
The results of this study demonstrated that the CHADS2
score is significantly associated with depressive symptoms
and QoL in a large general population. The tools of
WHOQOL-BREF and PHQ-9 were chosen to evaluate QoL
and depressive symptoms, respectively. With increasing
CHADS2 score, the prevalence of depressive symptoms
(PHQ-9 score ≥ 10) increases, while the total score and every
domain of WHOQOL-BREF decreases. The independent
associations were still observed after adjusting for confound-
ing risk factors.
Previous studies demonstrated that the components of
CHADS2 score were associated with depression and poor
QoL. Depression in patients with heart failure was 4–5
times that of the general population [28], and QoL was
greatly impaired among patients with heart failure [29]. A
systemic review showed that the general prevalence of
depression was as high as 26.8% among hypertensive
patients [14], and hypertension also impaired QoL [30].
Diabetes had a marked increase in depression prevalence,
however, a reduction in QoL [31]. Moreover, depression
was a common and serious complication after stroke, af-
fecting nearly 30% of patients at different stages [32]. The
possible reasons for lower QoL and depressive symptoms
among these patients included having chronic diseases,
being aware of them, and comprehensive treatment [33].
In this current study, only heart failure and stroke were in-
dependently associated with depressive symptoms, while
old age, hypertension, and diabetes mellitus had no signifi-
cant independent relation. All items in CHADS2 except
for hypertension were associated with impaired QoL.
These results were somewhat consistent with previous
ones. Relatively low education level, awareness, and treat-
ment of chronic diseases in rural China may partially con-
tribute to the differences [34, 35].
Fig. 1 Prevalence of depressive symptoms by CHADS2 score. Percentage of subjects with a PHQ-9 score≥ 10 increases with increasing CHADS2
score (P < 0.001). Error bars represent standard deviation. PHQ-9: Patient Health Questionnaire-9
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The scheme of the CHADS2 score has been used widely,
and a CHADS2 score ≥ 2 is considered as the risk factor
for stroke in AF patients. Recent study showed that
patients with a CHADS2 score ≥ 2 was also significantly
associated with peripheral arterial occlusive disease among
non-AF population [12]. The present study in the general
population demonstrated that subjects with CHADS2
score ≥ 3 had significantly higher risk of depressive symp-
toms than those with CHADS2 score = 0 after adjusting
for clinical covariates. Furthermore, CHADS2 score was
negatively associated with all scores of WHOQOL-BREF.
Previous study showed that depression was accompanied
Table 3 The mean score of WHOQOL-BREF based on CHADS2 score
CHADS2 score P value
0 (n = 4888) 1 (n = 4253) 2 (n = 1093) 3 (n = 598) 4 (n = 210) 5 (n = 18)
Overall Quality of life 3.30 ± 0.70 3.28 ± 0.68 3.23 ± 0.73 3.15 ± 0.63 3.02 ± 0.72 2.94 ± 0.64 <0.001
General health 3.49 ± 0.82 3.39 ± 0.83 3.24 ± 0.91 2.95 ± 0.89 2.64 ± 0.85 2.72 ± 1.02 <0.001
Domains
Physical health 15.5 ± 2.1 15.2 ± 2.2 14.5 ± 2.5 13.7 ± 2.5 12.5 ± 2.9 11.6 ± 3.1 <0.001
Psychological 14.7 ± 2.4 14.7 ± 2.4 14.2 ± 2.5 13.6 ± 2.5 12.9 ± 3.0 12.2 ± 3.0 <0.001
Social relationships 14.9 ± 2.1 14.7 ± 2.0 14.2 ± 2.2 13.9 ± 2.1 13.2 ± 2.4 12.6 ± 2.1 <0.001
Environment 13.6 ± 2.1 13.5 ± 2.1 13.3 ± 2.2 13.0 ± 2.1 12.7 ± 2.3 12.5 ± 1.9 <0.001
Total Score 65.4 ± 8.2 64.8 ± 8.0 62.7 ± 8.9 60.2 ± 8.4 57.0 ± 9.8 54.6 ± 9.2 <0.001
Data are expressed as mean ± standard deviation
Abbreviations: WHOQOL-BREF the World Health Organization Quality of Life Brief Scale






Unadjusted model Adjusted model 1 Adjusted model 2
OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value
Congestive heart failure
No 10,958 646 (5.9) 1 1 1
Yes 102 24 (23.5) 4.91 (3.09–7.81) <0.001 3.17 (1.91–5.25) <0.001 2.98 (1.79–4.96) <0.001
Hypertension
No 5437 281 (5.2) 1 1 1
Yes 5623 389 (6.9) 1.36 (1.16–1.60) <0.001 1.15 (0.96–1.37) 0.127 1.04 (0.87–1.24) 0.687
Age≥ 75 years
No 10,728 635 (5.9) 1 1 1
Yes 332 35 (10.5) 1.87 (1.31–2.68) 0.001 1.01 (0.68–1.51) 0.957 1.04 (0.70–1.55) 0.851
Diabetes mellitus
No 9906 567 (5.7) 1 1 1
Yes 1154 103 (8.9) 1.61 (1.30–2.01) <0.001 1.35 (1.07–1.72) 0.013 1.25 (0.98–1.59) 0.076
Stroke
No 10,084 542 (5.4) 1 1 1
Yes 976 128 (13.1) 2.66 (2.17–3.26) <0.001 2.02 (1.62–2.53) <0.001 1.96 (1.56–2.46) <0.001
CHADS2 score
0 4888 238 (4.9) 1 1
1 4253 229 (5.4) 1.11 (0.92–1.34) 0.265 1.02 (0.83–1.24) 0.872
2 1093 82 (7.5) 1.59 (1.22–2.06) 0.001 1.15 (0.87–1.53) 0.329
3 598 75 (12.5) 2.80 (2.13–3.69) <0.001 1.99 (1.47–2.68) <0.001
4 210 41 (19.5) 4.74 (3.29–6.83) <0.001 3.47 (2.29–5.25) <0.001
5 18 5 (27.8) 7.52 (2.66–21.25) <0.001 3.94 (1.28–12.12) 0.017
Adjusted model 1: adjusted for gender, body mass index, total cholesterol, triglyceride, low density lipid cholesterol, high density lipid cholesterol, serum uric acid,
estimated glomerular filtration rate, smoking, drinking, education, income, physical activity, and sleep time; Adjusted model 2: adjusted for factors in model 1 and
other items in CHADS2
Abbreviations: CI confidence interval, OR odds ratio, PHQ-9 Patient Health Questionnaire-9
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Fig. 2 Total score of WHOQOL-BREF by CHADS2 score stratified by depressive symptoms. The total score of WHOQOL-BREF decreases siginificantly
with increasing CHADS2 score in both subgroups (Ps < 0.001). Error bars represent standard deviation. PHQ-9: Patient Health Questionnaire-9;
WHOQOL-BREF: World Health Organization Quality of Life Brief Scale






scorePhysical health Psychological Social relationships Environment
Congestive heart failurea
β −0.106 −0.482 −1.771 −1.092 −0.528 −0.482 −4.458
P value 0.113 <0.001 <0.001 <0.001 0.008 0.016 <0.001
Hypertensiona
β 0.006 −0.073 −0.154 0.061 −0.097 0.075 −0.169
P value 0.690 <0.001 <0.001 0.193 0.018 0.071 0.284
Age≥ 75 yearsa
β 0.115 0.230 −0.492 −0.070 −0.581 −0.093 −0.877
P value 0.003 <0.001 <0.001 0.596 <0.001 0.426 0.047
Diabetes mellitusa
β −0.039 −0.190 −0.368 −0.307 −0.160 −0.132 −1.198
P value 0.191 <0.001 <0.001 0.003 0.072 0.145 <0.001
Strokea
β −0.091 −0.377 −1.192 −0.809 −0.469 −0.384 −3.298
P value <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
CHADS2 score
b
β −0.045 −0.170 −0.180 −0.098 −0.098 −0.058 −0.130
P value <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Abbreviations: CI confidence interval, WHOQOL-BREF the World Health Organization Quality of Life Brief Scale
aby multivariate linear regression analysis adjusted for gender, body mass index, total cholesterol, triglyceride, low density lipid cholesterol, high density lipid
cholesterol, serum uric acid, estimated glomerular filtration rate, smoking, drinking, education, income, physical activity, sleep time, and other items in CHADS2
bby optimal scale regression analysis adjusted for all factors in model α except for items in CHADS2
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by poor QoL with low scores of WHOQOL-BREF [36].
This study found that CHADS2 score was negatively asso-
ciated with the total score of WHOQOL-BREF whether
or not the subjects had depressive symptoms. This is the
first study to reveal the associations of CHADS2 score
with depressive symptoms and impaired QoL.
This study has several limitations. First, the current study
is cross-sectional and it was not clear whether the CHADS2
score would predict the incidence of depressive symptoms.
Second, congestive heart failure and stroke were diagnosed
based on a previous history of physician-diagnosis since a
large sample was involved. This approach may give rise to
an unintentional bias though it had been utilized in previ-
ous studies [23, 37]. Third, the current study was part of
NCRCHS, and subjects with severe mental disorders who
couldn’t complete the survey were excluded. This may have
a potential bias on the results. Fourth, the relatively small
sample in some subgroups may have reduced the statistical
power, and further studies with larger sample were needed
to confirm the results.
Conclusions
This is the first study to demonstrate that the CHADS2
score is significantly associated with depressive symptoms
and impaired QoL in the general Chinese population.
Much attention should also be paid to depressive symp-
toms and QoL among patients with high CHADS2 score.
Abbreviations
AF: Atrial fibrillation; CI: Confidence interval; CVD: Cardiovascular diseases;
DBP: Diastolic blood pressure; FBG: Fasting blood glucose; GFR: Glomerular
filtration rate; HDL-C: High density lipid cholesterol; LDL-C: Low density lipid
cholesterol; OR: Odds ratio; PHQ-9: Patient Health Questionnaire-9;
QoL: Quality of life; SBP: Systolic blood pressure; TC: Total cholesterol;
TG: Triglycerides; WHO: World Health Organization; WHOQOL-BREF: World
Health Organization Quality of Life Brief Scale
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